About Axcella
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence, the treatment of Long COVID, and the treatment of non-alcoholic steatohepatitis (NASH). The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.
Company Details
10M-25M
Biotechnology Research
51-200 employees
Public Company
Cambridge, MA
United States
Frequently Asked Questions about
What is Axcella's industry?
Axcella operates in the Biotechnology Research industry and is headquartered in United States.
How many employees does Axcella have?
Axcella has approximately 51-200 employees employees.
Where is Axcella's based?
Axcella is based in Cambridge, MA, United States.
Is Axcella publicly listed?
Yes. Axcella is a publicly traded company.
How can I contact Axcella's investor relations team?
You can reach Axcella’s investor relations department through the contact section on their official website or directly via the investor relations email listed in their latest SEC filings.
Find verified emails and phone numbers for professionals like those at
Up to 90% verified emails and mobile numbers, backed by weekly job-change alerts.
Find verified emails at this company
An email pattern tells you the format. It does not tell you who works there now or whether an address still delivers. Scalelist returns verified contacts, checked at the point you build the list.